



European Biotechnology

ISSN 2364-2351 | A 60711 | BIOCOM

Life Sciences and
Industry **Magazine**

Summer Edition 2018 | Volume 17 | 20 €

Interview

Novartis CEO
Vasant Narasimhan
reveals why he
bets on one-time
curative treatments
and digital
tools



FREE EXCERPT

Haemophilia A

Fixing the leak

Nanobots

Microscopic drug delivery systems – the next big thing

Agrochemistry

Bayer-Monsanto to bet on genome editing in crop design

Bioeconomy

Global policy leaders lay out agenda to push biologisation

Biofairs Compass

The ultimate guide to leading Life Sciences Events in H2/2018



Don't prepare. Just be ready.

C2MAP-2000 – 1 method, 17 mins, 95 media components

The new C2MAP-2000 automates all steps from pretreatment to measurement without any human intervention. It simplifies the workflow for optimizing cell culture conditions. There is no need to prepare. Just be ready.

Complete LCMS solution for cell culture analysis
combining the C2MAP-2000 pretreatment module with ultra-fast LCMS-8060

Highly efficient
through cutting culture media analysis time by 80 percent

Monitoring of up to 95 components
including amino acids, metabolites, sugars, vitamins and organic acids

Changes at a glance
with C2MAP-TRENDS viewer software visualizing temporal changes of components



Single-use plastics: New EU rules to reduce marine litter



MICHAEL CARUS The founder and Managing Director of the nova-Institute studied physics and mathematics at the University of Cologne. Carus became a lecturer at the University of Tübingen, on the topics of ecology, nuclear energy, and radioactivity. He worked as a science journalist and scientist at the KATALYSE Environmental Institute with a focus on energy, ecology, and renewable resources, and two years in the solar industry. In 1994, he founded the nova-Institute for Ecology and Innovation.

Plastics are magical materials, and they will be even more important in the future than they are today. But they lead to microplastics in the environment, especially noticeable as “marine littering.” The European Commission is now proposing, among other things, a ban on certain single-use plastic products, including “plastic cotton buds, cutlery, plates, straws, drink stirrers, and sticks for balloons, which will all have to be made exclusively from more sustainable materials instead.” The Commission’s legislative proposal must then be negotiated with the member states and the European Parliament. And here substantial changes should still be made – because so far industry and politics continued to fail in this area.

Microplastics have been in the public eye for at least ten years. The plastics industry has waited until the public pressure became too high to ignore. Then their argument was, what can our plastics do if people do not handle our products properly and politicians do not organise better recycling programmes? But in fact, the plastics industry can do something about it. For years, there has been another solution for plastic products that are practically impossible to recycle or whose preparation is far too costly: biodegradable plastics.


The European Commission has spent several million Euros over the last ten years to develop and certify such plastics. Plastics that are biodegradable in water, soil, home compost or industrial composting and do not leave any microparticles behind. And today there are many producers of biodegradable plastics; there are certifications and labels. But these new plastics are still a little too expensive to become sure-fire success. And now they don’t even get a chance in the new European plastics strategy!

Seize the opportunity for innovation and sustainability now. We prohibit single-use products if they are not biodegradable. But let us give biodegradable plastics, which have been successfully developed for years, their chance on the market! We also need alternatives to plastic products that, even when used properly, end up in the environment and are difficult or impossible to recycle. A few examples would be mulch films, tree protection covers, plant clips, binding yarns, strings for lawn trimmers, carrier polymers for fertilizers and pesticides, and even plastic baits at sea. Let us take a step forward in all of Europe. Because now is the time when the rules for the coming decades are being made.

Further reading: <http://bio-based.eu/policy/#innprobiofacts>

FREE EXCERPT

COVER STORY



12 Stopping the bleed

Since factor VIII replacement therapies hit the market, life expectancy for haemophilia patients has risen to normal levels. But around 25% of those who suffer from haemophilia A still have no therapeutic options, because their immune systems form antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US\$15bn haemophilia medications market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments, while a series of mergers and acquisitions have changed the playing field for established markets and players.

INSIGHT EUROPE

- 6 User-driven early certainty: EPO steps back
- 10 Launch of European PNAS; More rights for European CDMOs
- 11 European Commission proposes €100m budget for Horizon Europe

ECONOMY

- 17 Interview (Haemophilia): Gallia Levy, Global Development Team Leader, Hemlibra, Roche AG
- 19 Update on clinical trials
- 22 Interview (Strategy): Vas Narasimhan, CEO, Novartis AG

12

- 24 EMA News
- 25 Analyst commentary
- 26 Euro Biotech Stocks
- 28 Interview (Bioeconomy Finance): Rob Carlson, Managing Director, Bioeconomy Capital
- 30 Headwinds in sustainable industry and manufacturing
- 33 Falsified medicines deadline nears
- 34 Interview; Hannes Teissl, Polpharma Biologics
- 36 Interview: Federico Pollano, Rentschler Biopharma

REGIONAL NEWS

- 66 Northern Europe: Sweden, Denmark, Norway and Finland
- 68 Western Europe: France, Belgium, The Netherlands and the UK
- 70 Central Europe: Germany, Switzerland and Austria
- 72 Southern Europe: Italy, Spain, Greece, Slovenia, and Greece
- 74 Eastern Europe: Poland, Czech Republic and Hungary

SCIENCE & TECHNOLOGY


- 80 First mesenchymal stem cell therapy hits the European market
- 82 Approved diabetes medicine helps PAH patients

SERVICE

- 75 Biopeople
- 84 News from partner associations: Swiss Biotech Association, Medtec Europe and EuropaBio
- 88 Events
- 89 Company index/New products
- 90 Encore

IMPRINT European Biotechnology (ISSN 2364-2351) is published quarterly by: BIOCOM AG, Lützowstr. 33–36, D-10785 Berlin, Germany, Tel.: +49-30-264921-0, Fax: +49-30-264921-11, Email: service@european-biotechnology.com, Internet: www.european-biotechnology.com; Publisher: Andreas Mietzsch; Editorial Team: Thomas Gabrielczyk (Editor in Chief), Derrick Williams (Co-editor), Dr. Martin Laqua, Helene Märzhäuser, Sandra Wirsching; Advertising: Oliver Schnell, +49-30-2649-2145, Christian Böhm, +49-30-2649-2149, Andreas Macht, +49-30-2649-2154; Distribution: Marcus Laschke, +49-30-2649-2148; Graphic Design: Oliver-Sven Reblin; Production editor: Benjamin Röbig; Printed at: Königsdruck, Berlin; European Biotechnology Life Sciences & Industry Magazine is only regularly available through subscription at BIOCOM AG. Annual subscription fees: €80.00, Students €40.00 (subject to proof of enrolment). Prices include VAT, postage & packaging. Ordered subscriptions can be cancelled within two weeks directly at BIOCOM AG. The subscription is initially valid for one year. Subscriptions will be renewed automatically for one more year, respectively, unless they are cancelled at least six weeks before the date of expiry. Failures of delivery, which BIOCOM AG is not responsible for, do not entitle the subscriber to delivery or reimbursement of pre-paid fees. Seat of court is Berlin, Germany. As regards contents: individually named articles are published within the sole responsibility of their respective authors. All material published is protected by copyright. No article or part thereof may be reproduced in any way or processed, copied and proliferated by electronic means without the prior written consent of the publisher. Cover Photo: Naebly/istockphoto.com; Supplement: ASEBIO, EFIB/BIOCOM; ® BIOCOM is a registered trademark of BIOCOM AG, Berlin, Germany.

DRUG DELIVERY



60

Nanobot healthcare

They're small, fast – and could be the future of medicine. Nanobots have already been used in animal trials to attack tumours, and have proven effective. But there are still a few problems to overcome before doctors begin injecting millions of tiny machines into humans. Not least that researchers still have to figure out how to get rid of the microscopic helpers once they've done their job.

AGRI-BIOTECH

Consolidation up top

They co-created Agent Orange. Now agri-biotech giants Bayer and Monsanto are about to merge into a single mega-entity for pushing genetic engineering technologies in the crop design market. EUROPEAN BIOTECHNOLOGY takes a look at what consumers and farmers can expect, and how new products will be regulated in the age of the 'Big Four'.



76

EDITORIAL

Global discharge

At the recent Global Bioeconomy Summit (see. p. 30), US researcher John Schramski had an interesting message. He sees our planet as an accumulator that's been charged up by hundreds of millions of years of photosynthesis. Until now, he said, Earth has been able to effortlessly top up reserves. But as energy consumption by humans exploded over the past century, its currency of biomass and fossil fuel has been almost fully depleted. "We have to slow down," Schramski warns – because without our natural resources we won't survive.

An interesting aspect of the international meeting was that two major lobbies were apparent. There were those who pushed the idea that we all need to focus on sustainability, because no one knows how much longer we can go on exploiting our planet (see p. 32). On the other side were those who primarily see the economic opportunities attached to green technology (see p. 28).

Maybe biologisation of the industry is about both. Making money, but with the right biotechnologies for rebalancing economic, social and ecological imbalances.

The challenge now is to separate those who tout old technology to make money under green labels from those offering the right solutions.



Thomas Gabrielczyk
Editor-in-Chief


SPECIAL

Event compass

- 39 Intro: update on EU events
- 40 NLS Days, Stockholm
- 42 European Biotech Week
- 44 Biospain, Seville
- 46 bioLIVE, Madrid
- 48 BIO Japan, Yokohama
- 50 EFIB, Toulouse
- 52 European Business Development Conference, Hanover, Germany
- 54 BIO Europe, Copenhagen
- 56 Pharmalab, Düsseldorf
- 58 Biofit, Lille



Pictures: iordani/foolaa.com (top); iomerc/shutterstock.com (middle); AbiInc./iStock.com



Closing the gap in haemophilia therapy

FACTOR VIII INHIBITORS About 25% of the people who suffer from haemophilia A have no therapeutic options, because their immune system forms antibodies against clotting products that can stop bleeding. Researchers and companies in the growing US\$15.8bn haemophilia market are feverishly exploring new ways to identify patients at risk and offer them alternative treatments. A series of mergers and acquisitions have changed the playing field for established markets and players.

Every time Michael fell when he was a child, his parents had to rush him to the hospital. “Between the ages of one and six, we were there pretty much every day,” his mother remembers. Her son is one of 320,000 people worldwide with haemophilia A, the more common form of the genetic condition. People living with the hereditary disease either don’t produce enough of a clotting protein called factor VIII, or they lack it completely. Because their blood doesn’t clot properly, it can lead to uncontrolled bleeding. The disease is called ‘mild’ when FVIII levels are 5%-40% of normal levels, ‘moderate’ when between 1%-5%, and ‘severe’ when they’re under 1%. Michael has the severe form. Injections with factor VIII, the current standard of care, can prevent and treat bleeding episodes. “I try to do what I can, and not spend too much time thinking about what I can’t do,” says Michael, now a young man. “For me, that’s a kind of motto in life.” Starting in the 1950s, prophylactic factor VIII infusions were derived to treat haemophiliacs with plasma-derived factor VIII products from donors. In the 1990s, complementary treatments with recombinant factor VIII proteins hit the scene. Prophylactic factor VIII replacement therapy has now cut the average number of bleeds from more than 40 a year to under two. Today, a child born with severe haemophilia can expect to have a normal lifespan. But besides annual treatment costs of US\$150,000-\$300,000 per

patient, other serious hurdles remain. Prophylactic therapy patients continue to need drugs that will decrease their need for immunosuppressants. The half-life of the active factor VIII protein is also short, and needs to be extended. And most importantly, a significant number of patients simply don’t respond to treatment. Almost one in three people with severe haemophilia A also develops inhibitors –

antibodies that identify the recombinant blood clotting factor VIII as foreign, and stop it from working. For the big players in the currently US\$15.8bn field – Shire, Biogen/Bioverativ, Novo Nordisk, Pfizer and others (see table, p. 14) – new approaches to solving those problems could have a big impact on revenues. The market is growing. Analysts from Transparency Market Research predict it will surpass US\$25bn by 2024.

The huge unmet medical need and associated potential has triggered major acquisitions, with former market leaders under new ownership. Biogen haemophilia spinout Bioverativ, for instance, was taken over by Sanofi for US\$11.8bn. In a US\$62bn acquisition, haemophilia and haematology giant Shire plc agreed in May to a takeover by Takeda. Approaches for circumventing the immunogenicity and inhibitor problem – such as factor VIII products with fully human glycosylation patterns, gene therapies or bispecific antibodies that mimic the effects of factor VIII with less or no potential for inhibitor formation – have the potential to change the field dramatically.

Predicting inhibitor formation

However, current claims involving reduced immunogenicity and reduced [...]


» Read the full story in the printed issue.



ZOE WAIBLER Head Product Assessor for Immunologic Drugs, Paul Ehrlich Institute, Langen (Germany)

Why is it important to find factors in the blood that boost factor VIII inhibitor formation?

It’s a prerequisite for developing new approaches to haemophilia therapies, which prevent the formation of these inhibitors against factor-VIII products.



Nanobots: Fiction becoming reality

DRUG DELIVERY Once confined to speculative and science fiction, miniature micro- or nanobots targeting pathogens or conditions directly have now become reality in research labs worldwide. But to enter clinical trials, scientists still have to overcome two major hurdles – visualising the tiny machines inside the body, and preventing a potential immune response.

>> Read the full story in the printed issue.

FREE EXCERPT



A tractor entailing a fog of pesticides – a rare sight in a couple of years? Precision distribution of crop protecting agents via for instance drones could soon usher out mass spraying.

The future of agrochemistry

PESTICIDES & SEEDS One of the world's largest and most controversial mergers in the past few years was sealed in early June. German pharma and chemistry company Bayer has taken over US competitor Monsanto, forming the largest integrated provider of seeds, agrochemicals and digital farming solutions on the planet. The acquisition is part of a recent US\$170bn deal binge that is already having a profound impact on the future of global agriculture.


>> Read the full story in the printed issue.

3P Biopharmaceuticals S.L. (ES)	67	Kite Pharma (USA)	25
Abcam (UK)	25, 69	Lundbeckfond Ventures (DK)	66
Abylrx (B)	25	Medical Prognosis Institute A/S (DK)	66
Adama (IL)	77, 78	MediGene AG (DE)	25, 71
ADC Therapeutics SAS (CH)	20	Merck & Co. (USA)	20, 25
Affiris AG (AT)	70	Merck KGaA (DE)	25
Alvevon GmbH (DE)	75	Mesoblast Ltd. (AU)	82
Alexion Pharmaceuticals (USA)	67	Mobidiag Oy (FI)	67
Amgen Europe B.V. (CH)	24	Molecular Partners AG (CH)	70
Amplidag Oy (FI)	67	MolMed (IT)	69
Anergis SA (CH)	70	Mologen AG (DE)	19
ASEBIO (ES)	45, Supplement	Monsanto (USA)	77, 78, 79
Asit Biotech SA (B)	25	MorphoSys AG (DE)	68, 71
AstraZeneca AB (SE/UK)	19	Mymetics S.A. (CH)	70
Avexis Inc. (USA)	25, 71	Nestle S.A. (CH)	25
BASF AG (DE)	77, 78, 79	Neurimmune AG (CH)	71, 75
Bayer AG (DE)	19, 21, 25, 77, 78, 79	NMD Pharma A/S (DK)	66
BIA Separations d.o.o. (SLO)	73	Nordic Life Science Day (SE) 2018	41
BIOCOM AG (DE)	CP3	nova-Institut GmbH (DE)	29
BioFIT 2018 (F)	59	Novartis AG (CH)	22, 23, 71, 72
Biogen Idec (USA)	13, 71	Novo Nordisk A/S (DK)	13
Biognosys AG (CH)	65	Novo Seeds (DK)	66
BioJapan 2018 (JP)	49	Novozymes A/S (DK)	25, 31
Biological Industries (BI) Ltd. (USA)	83	NTC Pharma (IT)	72
Biomarin Pharmaceuticals (USA)	16	Nufarm Ltd. (AU)	78, 79
Biomay AG (AT)	73	Oncoarendi Therapeutics SA (PL)	74
Bioverativ (USA)	13	Oncology Venture Sweden AB (SE)	66
Biovertis AG (AT)	68	OPIS s.r.l. (IT)	19
bluebird bio (USA)	25, 71	Orchard Therapeutics (UK/USA)	69
Boehringer Ingelheim (DE)	69	Ose Immunotherapeutics SA (.	69
CANDOR Bioscience GmbH (DE)	23	Osiris Therapeutics (USA)	82
Capital Cell (ES)	73	Otsuka Pharmaceutical	
Cara Therapeutics (USA)	70	PepsiCo. (USA)	10
Cargill Inc. (USA)	79	Pfizer (USA)	16, 19
Cassiopea SPA (IT)	70	Polpharma Biologics (PL)	34, 35, CP4
Celgene Corp. (USA)	71	Polyphor Ltd. (CH)	70
Collectis (F)	25	Procter & Gamble (USA)	25
ChemChina (CN)	77	Promocell GmbH (DE)	89
Chugai Pharma Europe Ltd. (UK)	17	Puretech Health plc (USA)	75
Citoxlab Group (F)	74	Qiagen NV (DE)	71
Clovix Oncology UK Ltd.	24	Reckitt Benckiser (UK)	25
Coca-Cola (USA)	10	Redx Pharma (UK)	68, 75
Concept Heidelberg (DE)	57	Regeneron Pharmaceuticals Inc. (USA)	19, 21
Cosmo Pharmaceuticals NV (NL)	21	Rentschler Biotechnologie GmbH (DE)	36, 75
CPhI / BioLive 2018 (NL)	47	Roche Group (CH)	15, 16, 17, 19, 21, 25, 71
CRISPR Therapeutics (CH/USA)	20	Roche Venture Fund (CH)	66
Cynata Ltd. (AU)	82	Sangamo Biosciences Inc. (USA)	16
Deinove SA (F)	68	Sanitit (ES)	72
DGPharMed/DGPharmMed Annual Meeting 2019 (DE)	38	Sanofi SA (F)	13, 21, 25, 75
DowDuPont (USA)	77	Servier (F)	69
Dunn Labortechnik GmbH (GER)	11	Shimadzu (DE)	CP2
Dynabind GmbH (DE)	74	Shire plc (IRL)	13, 16, 69
EFIB 2018 (B)	51, Supplement	Shuwen Biotech (CN)	69
EBD Group (CH)	55	Siemens Healthineers (DE)	25
Endpoint AG - Bioprocess Center Europe (DE)	7	Solvo Biotechnology sro (HUN)	74
EuropaBio /European Biotech Week (EU)	43	Sophia Genetics (CH)	65
European Business Dev. Conf. 2018 (DE)	53	Sotio a.s. (CZ)	74
Evotec AG (DE)	71	Springvest (FI)	67
Exelixis, Inc. (USA)	20	Sunshine Kaidi Finland New Energy Co. Oy (CN/FIN)	67
FESIA (ES)	73	Syngenta AG (CH)	77, 78, 79
FGK Clinical Research GmbH (DE)	18	Takeda Pharma A/S (DK)	13, 16, 69, 82
FMC Agricultural Solutions (USA)	77, 78	Targovax AS (NO)	20
Freemome Inc. (USA)	71	Tech4Freedom (ES)	73
Genentech Inc. (USA)	17, 20, 21	Thrombogenics (B)	19
Genewave SAS (F)	67	TiGenix (B)	81, 82
Genmab A/S (DK)	20	Trianni, Inc. (USA)	15
GenSight Biologics (F)	19	TVM Capital Life Science (DE)	9, 68
Gilead Ltd. (USA)	25	uniQure BV (NL)	16
GlaxoSmithKline (UK)	25, 69	Versli Lietuva (LT)	35
Horizon Discovery Ltd. (UK)	25	Vertex Pharmaceuticals Inc. (USA)	20
Idorsia (CH)	70	Vetter Pharma-Fertigung GmbH & Co.KG.	21
INKEF Capital (NL)	66	Vifor Pharma AG (AT)	70
Intervac AB (SE)	67	Vivet Therapeutics (F)	67
Ionis Pharmaceuticals (USA)	71	Wilhelm Bähren GmbH & Co. KG (DE)	33
Janssen Biotech Inc. (USA)	20	Wilson Therapeutics AB (SE)	67
Jennewein Biotechnologie GmbH (DE)	20		

Cancer research

PROMOCELL PromoKine's Angiogenesis Assay Kit provides a simple, robust, easy to perform and semi-quantitative method to determine angiogenesis *in vitro* in less than 18 hours. It can be used for screening of angiogenesis modulators or studies of angiogenesis related signal transduction. The assay is based on the measurement of the ability of endothelial cells to form 3D structures (tube formation) under the influence of distinct stimulators, and uses a proprietary endotoxin-free and growth factor-reduced Extracellular Matrix Solution.

The Cell Migration/Chemotaxis Assay Kits are easy to use, sensitive and high throughput-adaptable systems. They uti-



lize a Boyden chamber, where the cells migrate through a semi-permeable membrane (three different pore sizes available) in response to stimulatory or inhibitory compounds.

The Cell Invasion Assay Kits also utilize a Boyden chamber that is coated with a layer of BME (Basement Membrane Extract), laminin, fibronectin, Collagen I or Collagen IV. The cells first traverse the matrix and then migrate through the semi-permeable membrane in the Boyden chamber in response to different stimuli. Cell migration as well as cell invasion can be analysed directly using a fluorescence plate reader. ▼

CONTACT

PromoCell GmbH
Sickingenstr 63/65, 69126 Heidelberg
www.promokine.info
info@promokine.info

14.|15.3.
2019

12th Berlin Conference on Life Sciences

Novel Antimicrobials and AMR Diagnostics


Save the date: On 14 and 15 March 2019, the Berlin Conference will once again be the meeting place for Life Science decision makers, business developers, investors and legal experts. The conference will explore the exciting market for the development of novel antimicrobials and AMR diagnostics.

Find more information at:

www.berlin-conferences.com

Drug substance and Fill&Finish

- Own CHO^{BC}® platform
- mABs
- New AB formats
- Proteins



www.polpharmabiologics.com
onestopshop@polpharma.com



YOUR MODULAR **ONE-STOP-SHOP**

FOR BIOPHARMACEUTICALS

